Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS
Listen now
Description
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” by Ford AC, Wright-Hughes A, Alderson S, et al. Lancet 2023; 402: 1773-85.
More Episodes
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry,” by Chugh R, Long MD, Jiang Y, Weaver KN, Beaulieu DB, Scherl EJ, Mahadevan U. Am J Gastroenterol. 2023 Oct...
Published 04/24/24
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “A phase 3, randomized controlled trial of resmetirom in NASH with liver fibrosis,” by Harrison SA, Bedossa P, Guy CD et al. NEJM 2024; 390(6): 497-509.
Published 04/24/24
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD discuss “Association of Glucagon-Like Peptide-1 Receptor Agonists with Serious Liver Events among Patients with Type 2 Diabetes Mellitus: A Scandinavian Cohort Study,” Engstom A, Wintzell V, Melbye M, et al. Hepatology 2024; In Press.
Published 04/24/24
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
